STEVIOL GLYCOSIDE RECOVERY

专利摘要:
recovery of steviol glycosides the present invention relates to a process for recovering one or more steviol glycosides from a fermentation broth containing steviol glycoside, the method of which comprises (a) the provision of a fermentation broth comprising one or more more steviol glycosides and one or more non-steviol glycoside components; (b) separating the liquid phase of the broth from the solid phase of the broth; (c) the provision of an adsorbent resin; (d) contacting the liquid phase of the broth with the adsorbent resin in order to separate at least part of the one or more steviol glycosides from the non-steviol glycoside components, in order to recover one or more steviol glycosides from the broth fermentation process containing one or more steviol glycosides. the invention also relates to a purified steviol glycoside composition prepared using such a process.
公开号:BR112016002092B1
申请号:R112016002092-8
申请日:2014-07-31
公开日:2020-12-15
发明作者:Igor Galaev
申请人:Dsm Ip Assets B.V.；
IPC主号:

专利说明:

Field of the Invention
[001] The present invention relates to a process for the recovery of one or more steviol glycosides from a fermentation broth containing steviol glycoside. The invention also relates to a composition obtainable by such a method. Background of the Invention
[002] The world demand for high potency sweeteners is increasing and, with the mixture of different artificial sweeteners, it is becoming a common practice. However, the demand for alternatives is expected to increase. The leaves of the perennial herb, Stevia rebaudiana Bert., Accumulate amounts of intensely sweet compounds known as steviol glycosides. While the biological function of these compounds is clear, they have commercial dignity as alternative high potency sweeteners, with the added advantage that Stevia sweeteners are natural plant products.
[003] These sweet steviol glycosides have functional and sensory properties that seem superior to those of many high potency sweeteners. In addition, studies suggest that stevioside may lower blood glucose levels in Type II diabetics and may lower blood pressure in mildly hypertensive patients.
[004] Steviol glycosides accumulate in Stevia leaves where they can comprise 10 to 20% of the dry weight of the leaf. Stevioside and rebaudioside A are both heat and pH stable and suitable for use in carbonated drinks and many other foods. Stevioside is between 110 and 270 times sweeter than sucrose, rebaudioside A between 150 and 320 times sweeter than sucrose. In addition, rebaudioside D is also a high potency diterpene glycoside sweetener that accumulates in Stevia leaves. It can be about 200 times sweeter than sucrose
[005] Currently, steviol glycosides are extracted from the Stevia plant. In Stevia, (-) - kaurenoic acid, an intermediate in the biosynthesis of gibberellic acid (GA), is converted to tetracyclic diterpene steviol, which then proceeds through a multistep glycosylation pathway to form the various steviol glycosides. However, yields can be variable and affected by agriculture and environmental conditions. Likewise, growing Stevia requires substantial land area, long before harvest, labor intensive and additional costs for the extraction and purification of glycosides.
[006] New, more standardized, glycoside sources with a unique pure composition with no residual flavor are required to satisfy the growing commercial demand for high potency natural sweeteners. Summary of the Invention
[007] Steviol glycosides can be produced fermentatively in recombinant microorganisms as set out in international copending patent application no. WO2013 / 110673 (PCT / EP2013 / 051262).
[008] The current invention relates to simplifying and improving the process of separating steviol glycosides from a fermentation broth comprising one or more such compounds.
[009] The invention thus provides a process in which fermentative-produced steviol glycosides can be separated from the other components of the fermentation broth. That is, the invention relates to a method for recovering one or more steviol glycosides from a fermentation broth comprising one or more such compounds. The invention also relates to compositions prepared using such a process.
[0010] The invention generally relates to the recovery of steviol glycosides from a fermentation broth using a chromatographic process. Accordingly, the invention relates to a process for recovering one or more steviol glycosides from a fermentation broth containing steviol glycoside, the method of which comprises: (a) providing a fermentation broth comprising one or more steviol glycosides and one or more non-steviol glycoside components; (b) separating the liquid phase of the broth from the solid phase of the broth; (c) provision of an adsorbent resin, for example in a filling column; (d) contacting the liquid phase of the broth with the adsorbent resin in order to separate at least part of the one or more steviol glycosides from the non-steviol glycoside components,
[0011] in order to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides.
The invention also relates to a process for recovering one or more steviol glycosides from a fermentation broth containing steviol glycoside, the method of which comprises: (a) providing a fermentation broth containing steviol glycoside; (b) provision of an adsorbent resin, for example, in a filling column in an expanded bed mode; (c) contacting the liquid phase of the broth with the adsorbent resin in order to separate at least part of the one or more steviol glycosides from the non-steviol glycoside components,
[0013] in order to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides.
[0014] The invention also refers to:
[0015] a solution comprising one or more steviol glycosides obtainable by a process according to the invention and;
[0016] a composition that comprises, on a dry solids basis, at least about 95% of Rebaudioside A, Rebaudioside D or Rebaudioside M produced in a fermentative manner. Brief Description of Drawings
[0017] Figure 1 establishes a schematic representation of the plasmid pUG7-EcoRV.
[0018] Figure 2 establishes a schematic representation of the method by which the ERG20, tHMG1 and BTS1 overexpression cassettes are designed (A) and integrated (B) in the yeast genome. (C) shows the final situation after removal of the KANMX marker by Cre recombinase.
[0019] Figure 3 establishes a schematic representation of the ERG9 expression reduction construct. This consisted of a 3 'wide 500 bp ERG9 portion, 98 bp of the TRP1 promoter, the open reading frame and TRP1 terminator, followed by a 400 bp wide downstream sequence of ERG9. Due to the introduction of an Xbal site at the end of the ERG9 open reading frame, the latest amino acid changes in Ser and the termination codon in Arg. A new termination codon is located on the TPR1 promoter, resulting in an extension of 18 amino acids.
[0020] Figure 4 establishes a schematic representation of how UGT2 is integrated into the genome. A. different fragments used in the transformation; B. situation after integration; C. situation after the expression of Cre recombinase.
[0021] Figure 5 establishes a schematic representation of how the GGPP pathway to RebA is integrated into the genome. A. different fragments used in the transformation; B. situation after integration.
[0022] Figure 6 establishes the extract elution pattern (1st run).
[0023] Figure 7 establishes the extract elution pattern (2nd run).
[0024] Figure 8 establishes a schematic diagram of the potential pathways that lead to the biosynthesis of steviol glycosides. String Listing Description
[0025] A description of the sequences is set out in Table 1. The sequences described in this document can be defined with reference to the sequence listing or with reference to the database access numbers also established in Table 1. Detailed Description of the Invention
[0026] Throughout this description and the appended claims, the words "comprise", "include" and "having" and variations such as "comprises", "comprising", "includes" and "including" are to be interpreted inclusive . That is, these words are intended as a convey the possible inclusion of other elements or whole numbers not specifically recited, where the context allows.
[0027] The articles "one" and "one" are used here to refer to one or more than one (that is, one or at least one) of the grammatical object of the article. For example, "an element" can mean one element or more than one element.
[0028] In this document, the term non-steviol glycoside means a substance that is not a steviol glycoside.
[0029] The invention relates to a process for recovering one or more steviol glycosides from a fermentation broth containing steviol glycoside, the method of which comprises: (a) providing a fermentation broth comprising one or more steviol glycosides and one or more non-steviol glycoside components; (b) separating a liquid phase of the broth from a solid phase of the broth; (c) contacting the liquid phase of the broth with an adsorbent resin in order to separate at least part of the one or more steviol glycosides from the non-steviol glycoside components,
[0030] in order to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides.
[0031] Typically, the adsorbent resin is provided in a filling column.
The invention also relates to a process for recovering one or more steviol glycosides from a fermentation broth containing steviol glycoside, the method of which comprises: (d) providing a fermentation broth containing steviol glycoside; (e) contacting the broth with an adsorbent resin in order to separate at least part of the one or more steviol glycosides from the non-steviol glycoside components,
[0033] in order to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides.
[0034] Typically, the adsorbent resin is provided in a filling column in an expanded bed mode.
[0035] The fermentation broth is a fermentation broth obtained from the fermentation of a microorganism, typically a recombinant microorganism, which is capable of producing one or more steviol glycosides. Such microorganisms and their fermentation are described in this document. Typically, the recombinant microorganism is one that is capable of extracellular production of one or more steviol glycosides.
[0036] Typically, the broth is treated before being applied to a chromatography column.
[0037] In particular, the cells can be tapped and the resulting solid and liquid phases separated. The cell can be disrupted, for example, by mechanical shock and heat. Such a disruption of the cell which may, however, not be necessary from the microorganism produced sufficient extracellular steviol glycoside (s). The solid / liquid separation can be carried out, for example, by centrifugation, membrane filtration or microfiltration.
[0038] The liquid can then be applied conveniently to a chromatography column.
[0039] An alternative separation of the liquid and solid phases may comprise spray drying of the broth (for example, a broth where the cells have been disrupted) and then extraction of steviol glycosides with a suitable solvent, for example, ethanol. In terms of this invention, this type of process is to be understood as constituting the "separation of a liquid phase of the broth from a solid phase of the broth". The resulting liquid can then be conveniently applied to a chromatography column.
[0040] The process of the invention can be carried out alternatively with the total broth (i.e., including the cells) where the process is carried out in the expanded bed format. The expanded bed adsorption allows the capture of proteins from raw materials containing particles without previous removal of particulates, thus allowing the clarification of a cell suspension or cell homogenate and the concentration of the desired product in a single operation. Another aspect of using the expanded mode is the possibility of removing in situ steviol glycosides from the broth while the cells and unbound nutrients are returned to the fermentation tank.
[0041] In the process of the invention, the adsorbent resin can be any suitable resin, for example, it is a polystyrene-divinylbenzene resin, a polymethacrylate resin, a polyaromatic resin, a functionalized polymethacrylate-divinylbenzene resin, a polystyrene-resin functionalized divinylbenzene or a methacrylate / divinylbenzene copolymer resin bound by amino (NH2).
[0042] The adsorbent resin can be functionalized with tertiary amines or quaternary amines.
[0043] In a process of the invention, the adsorbent may have a surface area of about 900 m2 / gram or greater.
[0044] The process according to the invention can be carried out in an adsorption / desorption chromatography format. In this format, the method comprises: (f) provision of a liquid phase (derived from a fermentation broth) or a fermentation broth and a solvent; (g) provision of an adsorbent resin; (h) provision of an eluting solvent; (i) contact of the adsorbent resin with the liquid phase or broth and elution solvent so that at least part of the non-steviol glycoside components adsorb on the adsorbent enriching the glycoside solution in steviol glycosides and resulting in the formation of a composition purified from steviol glycoside which is eluted from the adsorbent together with the eluting solvent; and (j) optionally, desorption of the non-steviol glycoside components from the adsorbent.
[0045] Typically, the adsorbent resin is provided in a filling column.
[0046] In such a process, the eluting solvent may comprise about 20% by weight or less of an alcohol and about 80% by weight or more of water.
[0047] In such a process, the eluting solvent may comprise about 50% by weight or less of an alcohol and about 50% by weight or more of water.
[0048] The process of the invention can be carried out in a format in which the separation method comprises fractionation chromatography. This process comprises the steps of: (k) provision of a liquid phase (derived from a fermentation broth) or a fermentation broth and a solvent; (l) provision of a column filled with an adsorbent; and (m) contacting the adsorbent with the liquid phase or broth so that at least a part of the non-steviol glycoside components adsorbed on the adsorbent and so that at least a part of the steviol glycoside adsorbed on the adsorbent, where the steviol glycosides propagate through the adsorbent at a faster rate than non-steviol glycosides; (n) collecting a solution containing steviol glycoside from the adsorbent.
[0049] In such a process, the solvent may comprise about 20% by weight or more of an alcohol and about 80% by weight or less of water.
[0050] In such a process, according to claim 9, wherein the solvent comprises about 25% to about 35% by weight of an alcohol and about 65% to about 75% water.
[0051] In such a process, the alcohol can be methanol, ethanol, propanol or butanol.
[0052] In such a process, the solvent may comprise water and the adsorbent may be a strongly acidic cation exchange resin.
[0053] In any format of the invention, more than one chromatographic cycle can be performed, for example, two, three, four, five or more chromatographic cycles.
[0054] In a process of the invention where two more chromatographic cycles are used, pH chromatography as such can be followed by chromatography at about pH 8.5 to reduce the concentration of Reb B. Reb B is one of the few rebaudiosides that had free carboxy group. Consequently, at high pH, where this group is loaded, RebB will have much less affinity for a hydrophilic adsorbent (for example, HP-20) and, consequently, will not bind to it at pH 8.5 while other uncharged rebaudiosides still remain. will call in the same way.
[0055] The process of the invention allows a purified steviol glycoside comprising the solution to be recovered. The solution containing recovered steviol glycoside typically has a purity that is at least about 10% greater, at least about 20% greater, at least about 30% when compared to a purity of the liquid phase or broth (of which at least one steviol glycoside is recovered).
[0056] In this document, the expression "separating at least a part of one or more steviol glycosides from non-steviol glycoside components" is to be understood as implying that at least a part of one or more steviol glycosides is separated from at least a portion of the non-steviol glycoside components. The term is not intended to imply that part of the one or more steviol glycosides recovered according to the process of the invention is necessary and completely free of non-steviol glycoside components. It is possible that the non-steviol glycoside components are recovered as well. However, the one or more steviol glycosides recovered must be enriched for the one or more steviol glycosides when compared to the raw material, for example, a fermentation broth. That is, the one or more steviol glycosides recovered according to the invention must comprise less non-steviol glycosides when compared to the raw material.
[0057] In a process of the invention, the solution containing purified steviol glycoside comprises, on a dry solids basis, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99% by weight of Rebaudioside A, Rebaudioside D or Rebaudioside M.
[0058] The solution can be further processed in a solid form, for example, a granulate or powder, for example, by spray drying or crystallization. Such a solid composition can comprise at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99% by weight of Rebaudioside A, Rebaudioside D or Rebaudioside M.
The invention thus provides a solution comprising one or more steviol glycosides obtainable by a process according to the invention. Such a solution may comprise one or more of steviolmonoside, steviolbioside, stevioside or rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rubusoside, dulcoside A or rebaudioside M.
[0060] Such a solution may comprise, on a dry solids basis, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99% by weight of Rebaudioside A, Rebaudioside D or Rebaudioside M.
[0061] Consequently, the invention provides a composition which may comprise, on a dry solids basis, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least at least about 95%, at least about 99% by weight of fermented produced Rebaudioside A, Rebaudioside D or Rebaudioside M.
[0062] Such a composition may be a granulate or powder obtainable by a process as set out above which includes a step of processing the solution comprising purified steviol in a solid form. Such a solid composition can comprise at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99% by weight of ebaudioside A, Rebaudioside D or Rebaudioside M produced fermentatively.
[0063] In the invention, the broth can be derived from the fermentation of any microorganism capable of producing a steviol glycoside.
[0064] In particular, a broth can be derived from a recombinant microorganism that is capable of producing a steviol glycoside. Suitable recombinant microorganisms are described in this document below. Such a recombinant microorganism can comprise one or more nucleotide sequence (s) that encode:
[0065] a polypeptide having ent copalyl pyrophosphate synthase activity;
[0066] a polypeptide having enthaurene synthase activity;
[0067] a polypeptide having enthaurene oxidase activity;
[0068] a polypeptide having kurenoic acid 13-hydroxylase activity; and one or more polypeptides having UDP-glycosyltransferase (UGT) activity, whereby the expression (s) of a nucleotide sequence gives the microorganism the ability to produce at least one steviol glycoside.
[0069] For the purposes of this invention, a polypeptide having ent-copalyl pyrophosphate synthase (EC 5.5.1.13) is capable of catalyzing the chemical reaction:

[0070] This enzyme has a substrate, geranylgeranyl pyrophosphate, and a product, ent-copalyl pyrophosphate. This enzyme precipitates in gibberellin biosynthesis. This enzyme belongs to the isomerase family, specifically, the class of intramolecular lyases. The systematic name of this class of enzyme is ent-copalyl-diphosphate lyase (de-cyclization). Other names in common use include having ent-copalyl pyrophosphate synthase, ent-kaurene synthase A and ent-kaurene synthase A.
[0071] For the purposes of this invention, a polypeptide having ent-kaurene synthase activity (EC 4.2.3.19) is a polypeptide that is capable of catalyzing the chemical reaction: ent-copalyl diphosphate Ent-kaurene + diphosphate
[0072] Consequently, this enzyme has a substrate, ent-copalyl diphosphate and two products, entururen and diphosphate.
[0073] This enzyme belongs to the family of lyases, specifically those carbon-oxygen lyases acting on phosphates. The systematic name of this class of enzyme is ent copalyl diphosphate diphosphate lyase (cyclization, formation of ent-kurene). Other names in common use include ent-kurene synthase B, ent-kurene synthase B, ent-copalyl-diphosphate diphosphate lyase and (cyclization). This enzyme participates in diterpenoid biosynthesis.
[0074] ent-copalyl diphosphate synthas may also have a distinct ent-kaurene synthase activity associated with the same protein molecule. The reaction catalyzed by ent-kaurene synthase is the next step on the biosynthetic pathway for gibberellins. The two types of enzyme activity are distinct and site-directed mutagenesis to suppress protein ent-kurene synthase activity leads to the accumulation of ent-copalyl pyrophosphate.
Consequently, a single nucleotide sequence can encode a polypeptide having ent-copalyl pyrophosphate synthase activity and ent-kaurene synthase activity. Alternatively, the two activities can be encoded in two separate separate nucleotide sequences.
[0076] For the purposes of this invention, a polypeptide having ent-kaurene oxidase activity (EC 1.14.13.78) is a polypeptide that is capable of catalyzing three successive oxidations of the 4-methyl group of ent-kaurene to give kaurenic acid. Such activity typically requires the presence of a cytochrome P450.
[0077] For the purposes of the invention, a polypeptide having kurenoic acid 13-hydroxylase activity (EC 1.14.13) is one that is capable of catalyzing the formation of steviol (ent-caur-16-en-13-ol- 19-oico) using NADPH and O2. Such an activity can also be referred to as ent-ca 13-hydroxylase activity.
A recombinant microorganism that can be fermented to produce a fermentation broth for use in the process of the invention comprises one or more nucleotide sequences that encode a polypeptide having UDP-glycosyltransferase (UGT) activity, whereby the expression (s) of a nucleotide sequence gives the microorganism the ability to produce at least one among steviolmonoside, steviolbioside, stevioside or rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rubusoside, dulcoside A or rebaudioside M.
[0079] For the purposes of this invention, a polypeptide having UGT activity is one that has glycosyltransferase activity (EC 2.4), that is, which can act as a catalyst for the transfer of a monosaccharide unit from an activated nucleotide sugar (also known as the "glycosyl donor") for a glycosyl acceptor molecule, usually an alcohol. The glycosyl donor for a UGT is typically the nucleotide sugar uridine diphosphate glucose (uracil diphosphate glucose, UDP-glucose).
[0080] The UGTs used can be selected to produce a desired diterpene glycoside, such as a steviol glycoside. Schematic diagrams of steviol glycoside formation are established in Humphrey et al, Plant Molecular Biology (2006) 61: 47-62 and Mohamed et al, J. Plant Physiology 168 (2011) 1136-1141. In addition, Figure 8 establishes a schematic diagram of steviol glycoside formation.
[0081] The biosynthesis of rebaudioside A involves the glycosylation of the aglycone steviol. Specifically, rebaudioside A can be formed by glycosylation of the steviol 13-OH which forms the 13-O-steviolmonoside, C-2 'glycosylation of the steviolmonoside 13-O-glucose which forms steviol-1,2-bioside, glycosylation steviol-1,2-bioside C-19 carboxyl forming stevioside, and stevioside C-3 'glycosylation C-3'. The order in which each glycosylation reaction occurs can vary - see Figure 8. A UGT may be able to catalyze more than one conversion as set out in this scheme.
[0082] The conversion of steviol to rebaudioside A or rebaudioside D can be performed in a recombinant host by expression of gene (s) encoding the following functional UGTs: UGT74G1, UGT85C2, UGT76G1 and UGT2. Thus, a recombinant microorganism that expresses these four UGTs can make rebaudioside A if it produces steviol or when it feeds steviol in the medium. Typically, one or more of these genes are recombinant genes that have been transformed into a microorganism that does not naturally possess them. Examples of all of these enzymes are set out in Table 1. A recombinant microorganism can comprise any combination of a UGT74G1, UGT85C2, UGT76G1 and UGT2. In Table 1, UGT64G1 sequences are indicated as UGT1 sequences, UGT74G1 sequences are indicated as UGT3 sequences and UGT76G1 sequences are indicated as UGT4 sequences. The UGT2 sequences are indicated as UGT2 sequences in Table 1.
[0083] A recombinant microorganism comprising a nucleotide sequence that encodes a polypeptide having UGT activity may comprise a nucleotide sequence that encodes a polypeptide capable of catalyzing the addition of a C-13-glucose in steviol. That is, a recombinant microorganism can comprise a UGT that is capable of catalyzing a reaction in which steviol is converted to steviolmonoside. Consequently, the expression of such a nucleotide sequence can give the microorganism the ability to produce at least steviolmonoside.
[0084] Such a microorganism can comprise a nucleotide sequence that encodes a polypeptide having the activity shown by UDP-glycosyltransferase (UGT) UGT85C2, whereby a nucleotide sequence by transforming the microorganism gives the cell the ability to convert steviol to steviolmonoside.
[0085] The activity of UGT85C2 is to transfer from a glucose unit to steviol 13-OH. Thus, a suitable UGT85C2 can function as a 5'-diphospho glycosyl uridine: steviol 13-OH transferase and a 5'-transferase uridine. A functional UGT85C2 polypeptide can also catalyze glycosyl transferase reactions that use steviol glycoside substrates other than steviol and steviol-19-O-glycoside. Such sequences are indicated as UGT1 sequences in Table 1.
A recombinant microorganism comprising a nucleotide sequence that encodes a polypeptide having UGT activity may comprise a nucleotide sequence that encodes a polypeptide capable of catalyzing the addition of a C-13-glucose in steviol or steviolmonoside. That is, a recombinant microorganism can comprise a UGT that is capable of catalyzing a reaction in which steviolmonoside is converted to steviolbioside. Consequently, such a microorganism may be able to convert steviolmonoside to steviolbioside. Expression of such a nucleotide sequence can give the microorganism the ability to produce at least steviolbioside.
A suitable recombinant microorganism can also comprise a nucleotide sequence that encodes a polypeptide having the activity shown by UDP-glycosyltransferase (UGT) UGT74G1, whereby a nucleotide sequence by transforming the microorganism gives the cell the ability to convert steviolmonoside to steviolbioside.
[0088] A suitable recombinant microorganism can also comprise a nucleotide sequence that encodes a polypeptide having the activity shown by UDP-glycosyltransferase (UGT) UGT2, whereby a nucleotide sequence upon transformation of the microorganism gives the cell the ability to convert steviolmonoside to steviolbioside.
[0089] A suitable UGT2 polypeptide functions as a 5'-diphospho glycosyl uridine: steviol-13-O-glycoside transferase (also referred to as a steviol-13-monoglycoside 1,2-glycosylase), transferring a portion of glucose to C -2 'of the 13-O-glucose of the acceptor molecule, steviol-13-O-glycoside. Typically, a suitable UGT2 polypeptide also functions as a 5'-diphosphal glycosyl: rubusoside transferase transferring a portion of glucose to the C-2 'of the 13-O-glucose of the acceptor molecule, rubusoside.
[0090] UGT2 functional polypeptides can also catalyze reactions using steviol glycoside substrates other than steviol-13-O-glycoside and rubusoside, for example, UGT2 functional polypeptides can use stevioside as a substrate, transferring a portion of glucose to the C-2 'of the 19-O-glucose residue to produce Rebaudioside E. A UGT2 functional polypeptide can also use Rebaudioside A as a substrate, transferring a portion of glucose to the C-2' of the 19-O-glucose residue to produce Rebaudioside D. However, a functional UGT2 polypeptide typically does not transfer a portion of glucose to steviol compounds having a 1,3-glucose bound at the C-13 position, that is, the transfer of a portion of glucose to steviol 1,3-bioside and 1,3-stevioside do not occur.
[0091] UGT2 functional polypeptides can also transfer sugar portions from donors other than uridine diphosphate glucose. For example, a functional UGT2 polypeptide can act as a 5'-diphospho D-xylosyl uridine: steviol-13-O-glycoside transferase, transferring a portion of xylose to the C-2 'of the 13-O-glucose from the acceptor molecule, steviol-13-O-glycoside. As another example, a functional UGT2 polypeptide can act as a 5'-diphospho-L-ramnosyl uridine: steviol-13-O-glycoside transferase, transferring a portion of rhamnose to the C-2 'of the 13-O-glucose from the acceptor molecule , steviol-13-O-glycoside. Such sequences are indicated as UGT2 sequences in Table 1.
[0092] A recombinant microorganism that can be fermented to produce a fermentation broth for use in a process of the invention comprising a nucleotide sequence that encodes a polypeptide having UGT activity may comprise a nucleotide sequence that encodes a polypeptide able to catalyze the addition of a C-19-glucose to steviolbioside. That is, a suitable recombinant microorganism can comprise a UGT that is capable of catalyzing a reaction in which the steviolbioside is converted to stevioside. Consequently, such a microorganism may be able to convert the steviolbioside to stevioside. Expression of such a nucleotide sequence can give the microorganism the ability to produce at least the stevioside.
[0093] A suitable recombinant microorganism may also comprise a nucleotide sequence that encodes a polypeptide having the activity shown by UDP-glycosyltransferase (UGT) UGT74G1, whereby a nucleotide sequence upon transformation of the microorganism gives the cell the ability to convert steviolbioside to stevioside.
[0094] Suitable UGT74G1 polypeptides may be able to transfer a glucose unit to 13-OH or 19-COOH, respectively, of steviol. A suitable UGT74G1 polypeptide can function as a 5'-diphosphal glycosyl: steviol 19-COOH transferase and a 5'-diphospho glycosyl uridine: steviol-13-O-glycoside 19-COOH transferase. Functional UGT74G1 polypeptides can also catalyze glycosyl transferase reactions that use steviol glycoside substrates other than steviol and steviol-13-O-glycoside or that transfer portions of sugar from donors other than uridine diphosphate glucose. Such sequences are indicated as UGT1 sequences in Table 3.
[0095] A recombinant microorganism comprising a nucleotide sequence encoding a polypeptide having UGT activity may comprise a nucleotide sequence encoding a polypeptide capable of catalyzing the glycosylation of the C-3 'of glucose at the C-13 position of stevioside. That is, a recombinant microorganism can comprise a UGT that is capable of catalyzing a reaction in which stevioside into rebaudioside A. Consequently, such a microorganism may be able to convert stevioside into rebaudioside A. The expression of such a nucleotide sequence can give the microorganism the ability to produce at least rebaudioside A.
A suitable recombinant microorganism may also comprise a nucleotide sequence that encodes a polypeptide having the activity shown by UDP-glycosyltransferase (UGT) UGT76G1, whereby a nucleotide sequence by transforming the microorganism gives the cell the ability to convert stevioside to rebaudioside A.
[0097] A suitable UGT76G1 adds a portion of glucose to the C-3 'of the C-13-O-glucose of the acceptor molecule, a steviol 1.2 glycoside. Thus, UGT76G1 functions, for example, as a 5'-diphospho glycosyl uridine: steviol 130-1.2 glycoside C-3 'glycosyl transferase and a 5'-diphosphal glycosyl uridine: steviol-19-0-glucose, 13-0 -1.2 bioside C-3 'glycosyl transferase. Functional UGT76G1 polypeptides can also catalyze glycosyl transferase reactions using steviol glycoside substrates that contain sugars other than glucose, for example, steviol ramnosides and steviol xylosides. Such sequences are indicated as UGT4 sequences in Table 1.
[0098] A recombinant microorganism can comprise nucleotide sequences that encode polypeptides having one or more of the four UGT activities described above. Preferably, a recombinant microorganism can comprise nucleotide sequences that encode polypeptides having all four of the UGT activities described above. A given nucleic acid can encode a polypeptide having one or more of the above activities. For example, a nucleic acid encodes a polypeptide that has two, three or four of the activities set out above. Preferably, a recombinant microorganism comprises the activity of UGT1, UGT2 and UGT3. More preferably, such a recombinant microorganism will also comprise UGT4 activity.
[0099] A recombinant microorganism comprising a nucleotide sequence encoding a polypeptide having UGT activity may comprise a nucleotide sequence encoding a polypeptide capable of catalyzing the glycosylation of stevioside or rebaudioside A. That is, a microorganism The recombinant can comprise a UGT that is capable of catalyzing a reaction in which stevioside or rebaudioside A is converted to rebaudioside D. Consequently, such a microorganism may be able to convert stevioside or rebaudioside A into rebaudioside D. The expression of such a sequence of nucleotide can give the microorganism the ability to produce at least rebaudioside D. It has been shown that a microorganism that expresses a combination of UGT85C2, UGT2, UGT74G1 and UGT76G1 polypeptides may be able to produce rebaudioside D.
[00100] A microorganism comprising a nucleotide sequence that encodes a polypeptide having UGT activity can comprise a nucleotide sequence that encodes a polypeptide capable of catalyzing stevioside glycosylation. That is, a microorganism can comprise a UGT that is able to catalyze a reaction in the stevioside is converted to E rebaudioside. Consequently, such a micro-organism may be able to convert stevioside into E rebaudioside. give the microorganism the ability to produce at least E rebaudioside.
[00101] A microorganism comprising a nucleotide sequence that encodes a polypeptide having UGT activity may comprise a nucleotide sequence that encodes a polypeptide capable of catalyzing the glycosylation of rebaudioside E. That is, a microorganism may comprise a UGT that is capable of catalyzing a reaction in which rebaudioside E is converted to rebaudioside D. Consequently, such a microorganism may be able to convert stevioside or rebaudioside A into rebaudioside D. The expression of such a nucleotide sequence may give the microorganism the capacity to produce at least rebaudioside D.
[00102] A recombinant microorganism may be able to express a nucleotide sequence that encodes a polypeptide having NADPH-cytochroma p450 reductase activity. That is, a recombinant microorganism can comprise a sequence that encodes a polypeptide having NADPH-cytochroma p450 reductase activity.
[00103] A polypeptide having NADPH-cytochroma p450 reductase activity (EC 1.6.2.4; also known as NADPH: ferri-hemoprotein oxidoreductase, NADPH: hemoprotein oxidoreductase, NADPH: P450 oxidoreductase, P450 reductase, POR, is typically, CPR, CY) one that is a membrane-bound enzyme allowing electron transfer to cytochrome P450 in the eukaryotic cell microsome of a NADPH enzyme: cytochrome P450 reductase (POR; EC 1.6.2.4) containing FAD and FMN.
[00104] Preferably, a recombinant microorganism, capable of being fermented to prepare a fermentation broth suitable for use in the process of the invention, is capable of expressing one or more of: a. a nucleotide sequence that encodes a polypeptide having NADPH-cytochrome P450 reductase activity, wherein the said nucleotide sequence comprises: i. a nucleotide sequence encoding a polypeptide having NADPH-cytochroma p450 reductase activity, said polypeptide comprising an amino acid sequence that is at least about 20%, preferably at least 25, 30, 40, 50, 55, 60, 65 , 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with an amino acid sequence of SEQ ID NOs: 54, 56, 58 or 78; ii. a nucleotide sequence that is at least about 15%, preferably at least 20, 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity to a nucleotide sequence of SEQ ID NOs: 53, 55, 57 or 77; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code,
[00105] Preferably, a recombinant microorganism is one that is capable of expressing one or more of: a. a nucleotide sequence that encodes a polypeptide having ent-copalyl pyrophosphate synthase activity, wherein the said nucleotide sequence comprises: i. a nucleotide sequence encoding a polypeptide having ent-copalyl pyrophosphate synthase activity, said polypeptide comprising an amino acid sequence that is at least about 20%, preferably at least 25, 30, 40, 50, 55, 60, 65 , 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with an amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 18, 20, 60 or 62; ii. a nucleotide sequence that is at least about 15%, preferably at least 20, 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with a nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, 17, 19, 59 or 61, 141, 142, 151, 152, 153, 154, 159, 160, 182 or 184; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code, b. a nucleotide sequence that encodes a polypeptide having ent-synthase activity, wherein the said nucleotide sequence comprises: i. a nucleotide sequence encoding a polypeptide having ent-kaurene synthase activity, said polypeptide comprising an amino acid sequence that is at least about 20%, preferably at least 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with an amino acid sequence of SEQ ID NOs: 10, 12, 14, 16, 18, 20, 64 or 66 ; ii. a nucleotide sequence that is at least about 15%, preferably at least 20, 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with a nucleotide sequence of SEQ ID NOs: 9, 11, 13, 15, 17, 19, 63, 65, 143, 144, 155, 156, 157, 158, 159, 160, 183 or 184; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code, c. a nucleotide sequence encoding a polypeptide having enthalurene oxidase activity, wherein the said nucleotide sequence comprises: i. a nucleotide sequence encoding a polypeptide having ent-kaurene oxidase activity, said polypeptide comprising an amino acid sequence that is at least about 20%, preferably at least 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with an amino acid sequence of SEQ ID NOs: 22, 24, 26, 68 or 86; ii. a nucleotide sequence that is at least about 15%, preferably at least 20, 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity to a nucleotide sequence of SEQ ID NOs: 21, 23, 25, 67, 85, 145, 161, 162, 163, 180 or 186; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code; or d. a nucleotide sequence that encodes a polypeptide having kurenoic acid 13-hydroxylase activity, wherein the said nucleotide sequence comprises: i. a nucleotide sequence encoding a polypeptide having kurenoic acid 13-hydroxylase activity, said polypeptide comprising an amino acid sequence that is at least about 20%, preferably at least 25, 30, 40, 50, 55, 60, 65 , 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with an amino acid sequence of SEQ ID NOs: 28, 30, 32, 34, 70, 90, 92, 94, 96 or 98; ii. a nucleotide sequence that is at least about 15%, preferably at least 20, 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity to a nucleotide sequence of SEQ ID NOs: 27, 29, 31, 33, 69, 89, 91, 93, 95, 97, 146, 164, 165, 166, 167 or 185; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code.
[00106] In a recombinant microorganism that is capable of expressing a nucleotide sequence that encodes a polypeptide capable of catalyzing the addition of a C-13-glucose in steviol, said nucleotide may comprise: i. a nucleotide sequence encoding a polypeptide capable of catalyzing the addition of a C-13-glucose in steviol, said polypeptide comprising an amino acid sequence that is at least about 20%, preferably at least 25, 30, 40, 50 , 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with an amino acid sequence of SEQ ID NOs: 36, 38 or 72; ii. a nucleotide sequence that is at least about 15%, preferably at least 20, 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity to a nucleotide sequence of SEQ ID NOs: 35, 37, 71, 147, 168, 169 or 189; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code.
[00107] In a recombinant microorganism that is capable of expressing a nucleotide sequence that encodes a polypeptide capable of catalyzing the addition of a glucose at the C-13 position of steviolmonoside (this typically indicates the glycosylation of C-2 'of C Glucose / steviolmonoside 13-0-glucose), the said nucleotide sequence may comprise: i. a nucleotide sequence encoding a polypeptide capable of catalyzing the addition of a C-13-glucose to steviol or steviolmonoside, said polypeptide comprising an amino acid sequence that is at least about 20%, preferably at least 25, 30, 40 , 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with an amino acid sequence of SEQ ID NOs: 88, 100, 102, 104, 106, 108, 110 or 112; ii. a nucleotide sequence that is at least about 15%, preferably at least 20, 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity to a nucleotide sequence of SEQ ID NOs: 87, 99, 101, 103, 105, 107, 109, 111, 181 or 192; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code.
[00108] In a recombinant microorganism that is capable of expressing a nucleotide sequence that encodes a polypeptide capable of catalyzing the addition of a glucose at the C-19 position of steviolbioside, the said nucleotide sequence may comprise: i. a nucleotide sequence that encodes a polypeptide capable of catalyzing the addition of a glucose at the C-19 position of steviolbioside, said polypeptide comprising an amino acid sequence that has at least about 20% sequence identity with an amino acid sequence of SEQ ID NOs: 40, 42, 44, 46, 48 or 74; ii. a nucleotide sequence that has at least about 15% sequence identity with a nucleotide sequence of SEQ ID NOs: 39, 41, 43, 45, 47, 73, 148, 170, 171, 172, 173, 174 or 190; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code.
[00109] In a recombinant microorganism that expresses a nucleotide sequence that encodes a polypeptide capable of catalyzing glycosylation of the C-3 'of glucose at the C-13 position of stevioside, the said nucleotide sequence may comprise: i. a nucleotide sequence encoding a polypeptide capable of catalyzing glycosylation of glucose C-3 'at the C-13 position of stevioside, said polypeptide comprising an amino acid sequence that is at least about 20%, preferably at least 25, 30 , 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity with an amino acid sequence of SEQ ID NOs: 50, 52 or 76; ii. a nucleotide sequence that is at least about 15%, preferably at least 20, 25, 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% sequence identity to a nucleotide sequence of SEQ ID NOs: 49, 51, 75, 149, 175, 176 or 191; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code.
[00110] In a recombinant microorganism that expresses a nucleotide sequence that encodes a polypeptide capable of catalyzing one or more of: the glycosylation of stevioside or rebaudioside A in rebaudioside D; the glycosylation of stevioside in rebaudioside E; or the glycosylation of rebaudioside E in rebaudioside D, the said nucleotide sequence may comprise: i. a nucleotide sequence that encodes a polypeptide capable of catalyzing one or more of: the glycosylation of stevioside or rebaudioside A in rebaudioside D; the glycosylation of stevioside in rebaudioside E; or the glycosylation of rebaudioside E in rebaudioside D, said polypeptide comprising an amino acid sequence that has at least about 20% sequence identity with an amino acid sequence of SEQ ID NOs: 88, 100, 102, 104, 106, 108, 110, 112; ii. a nucleotide sequence that has at least about 15% sequence identity with a nucleotide sequence of SEQ ID NOs: 87, 99, 101, 103, 105, 107, 109, 111, 181 or 192; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code.
[00111] A suitable microorganism may be one in which the microorganism's ability to produce geranylgeranyl pyrophosphate (GGPP) is overloaded. Overloaded in the context of this invention implies that the microorganism produces more GGPP than an equivalent untransformed strain.
Accordingly, a suitable recombinant microorganism may comprise one or more nucleotide sequence (s) encoding hydroxymethylglutaryl-CoA reductase, farnesyl-pyrophosphate synthase and geranylgeranyl diphosphate synthase, whereby a nucleotide sequence (s) upon transformation microorganism gives the microorganism the ability to produce high levels of GGPP.
[00113] Preferably, a suitable recombinant microorganism is one that is capable of expressing one or more of: a. a nucleotide sequence that encodes a polypeptide having hydroxymethylglutaryl-CoA reductase activity, wherein the said nucleotide sequence comprises: i. a nucleotide sequence encoding a polypeptide having hydroxymethylglutaryl-CoA reductase activity, said polypeptide comprising an amino acid sequence that has at least about 20% sequence identity with an amino acid sequence of SEQ ID NO: 80; ii. a nucleotide sequence that has at least about 15% sequence identity with a nucleotide sequence of SEQ ID NO: 79; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code, b. a nucleotide sequence that encodes a polypeptide having farnesyl-pyrophosphate synthase activity, wherein the said nucleotide sequence comprises: i. a nucleotide sequence encoding a polypeptide having farnesylpyrophosphate synthase activity, said polypeptide comprising an amino acid sequence that has at least about 20% sequence identity with an amino acid sequence of SEQ ID NO: 82; ii. a nucleotide sequence that has at least about 15% sequence identity with a nucleotide sequence of SEQ ID NOs: 81; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule from (iii) due to the degeneration of the genetic code; or c. a nucleotide sequence encoding a polypeptide having geranylgeranyl diphosphate synthase activity, wherein the said nucleotide sequence comprises: i. a nucleotide sequence encoding a polypeptide having geranylgeranyl diphosphate synthase activity, said polypeptide comprising an amino acid sequence that has at least about 20% sequence identity with an amino acid sequence of SEQ ID NO: 84; ii. a nucleotide sequence that has at least about 15% sequence identity with a nucleotide sequence of SEQ ID NOs: 83; iii. a nucleotide sequence whose complementary strand hybridizes to a nucleic acid molecule of the sequence of (i) or (ii); or iv. a nucleotide sequence that differs from a sequence of a nucleic acid molecule of (i), (ii) or (iii) due to the degeneration of the genetic code.
[00114] A microorganism or microbe, for the purposes of this invention, is typically an organism that is not visible to the human eye (i.e., microscopic). A microorganism can be bacteria, fungi, archebacteria or protists. Typically, a microorganism will be a single cell or single cell organism.
[00115] As used herein, a recombinant microorganism is defined as a microorganism that is genetically modified or transformed / transfected with one or more of the nucleotide sequences as defined in this document. The presence of one or more such nucleotide sequences alters the microorganism's ability to produce a diterpene or diterpene glycoside, in particular steviol or steviol glycoside. A microorganism that is not transformed / transfected or genetically modified is not a recombinant microorganism and typically does not comprise one or more of the nucleotide sequences that allow the cell to produce a glycoside diterpene or diterpene. Consequently, an untransformed / non-transfected microorganism is typically a microorganism that does not naturally produce a diterpene, although a microorganism that naturally produces a diterpene or diterpene glycoside and that has been modified, as described in this document, for example, (and thus has an altered ability to produce a glycoside diterpene / diterpene), is considered a recombinant microorganism.
[00116] Sequence identity is hereby defined as a relationship between two or more amino acid sequences (polypeptide or protein) or two or more nucleic acid sequences (polynucleotide), as determined by comparing the sequences. Generally, sequence identities or similarities are compared over the entire length of the compared sequences. In the art, "identity" also means the degree of relationship of a sequence between amino acid or nucleic acid sequences, as the case may be, as determined by the correspondence between strands of such sequences. "Identity" and "similarity" can be readily calculated by various methods, known to those skilled in the art. The preferred methods for determining identity are designed to match the tested strings as closely as possible. Typically below, identities and similarities are calculated over the entire length of the strings being compared. The methods for determining identity and similarity are codified in publicly available computer programs. Preferred computer program methods for determining the identity and similarity between two sequences include, for example, BestFit, BLASTP, BLASTN, and FASTA (Altschul, SF et al., J. Mol. Biol. 215: 403-410 (1990), publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894). Preferred parameters for comparing amino acid sequences using BLASTP are gap gap 10.0 , gap length 0.5, Blosum 62 matrix. Preferred parameters for comparing nucleic acid sequences using BLASTP are gap gap 10.0, gap length 0.5, complete DNA matrix (DNA identity matrix).
[00117] The nucleotide sequences encoding the enzymes expressed in the cells described in this document can also be defined by their ability to hybridize the nucleotide sequences of SEQ ID NO.'s 1, 3, 5, 7, 9, 1 1, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81 or 84 or any other sequence mentioned in this document, respectively, under moderate or preferably severe hybridization conditions. Severe hybridization conditions are hereby defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and more preferably about 200 or more nucleotides, to hybridize at a temperature of about 65 ° C in a solution comprising about 0.1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength and washing at 65 ° C in a solution comprising about 0.1 M salt or less, preferably 0.2 x SSC or any other solution having a comparable ionic resistance. Preferably, the hybridization is carried out overnight, that is, for at least 10 hours and preferably the washing is carried out for at least one hour with at least two changes of the washing solution. These conditions will generally allow for specific sequence hybridization having about 90% or more sequence identity.
[00118] Moderate conditions are hereby defined as conditions that allow a nucleic acid sequence of at least 50 nucleotides, preferably about 200 or more nucleotides to hybridize at a temperature of about 45 ° C in a solution comprising about salt at 1 M, preferably 6 x SSC or any other solution having a comparable ionic resistance, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic resistance. Preferably, the hybridization is carried out overnight, that is, at least for 10 hours, and preferably the washing is carried out for at least one hour with at least two changes of the washing solution. These conditions will generally allow for sequence specific hybridization having up to 50% sequence identity. The person skilled in the art will be able to modify these hybridization conditions in order to specifically identify sequences that vary in identity between 50% and 90%.
[00119] The nucleotide sequences encoding an ent-copalyl pyrophosphate synthase; ent-kaurene synthase; ent-kaurene oxidase; kaurenoic acid 13-hydroxylase; UGT; hydroxymethylglutaryl-CoA reductase, farnesyl-pyrophosphate synthetase; geranylgeranyl diphosphate synthase; NADPH- cytochroma p450 reductase, can be of prokaryotic or eukaryotic origin.
[00120] A nucleotide sequence encoding an ent-copalyl pyrophosphate synthase can, for example, comprise a sequence as set out in SEQ ID. NO: 1, 3, 5, 7, 17, 19, 59, 61, 141, 142, 151, 152, 153, 154, 159, 160, 182 or 184.
[00121] A nucleotide sequence encoding an ent-kaurene synthase can, for example, comprise a sequence as set out in SEQ ID. NO: 9, 11, 13, 15, 17, 19, 63, 65, 143, 144, 155, 156, 157, 158, 159, 160, 183 or 184.
[00122] A nucleotide sequence encoding an ent-kaurene oxidase can, for example, comprise a sequence as set out in SEQ ID. NO: 21, 23, 25, 67, 85, 145, 161, 162, 163, 180 or 186. A predicted KO is the polypeptide encoded by the nucleic acid set forth in SEQ ID NO: 85.
A nucleotide sequence encoding a 13-hydroxylase kurenoic acid can, for example, comprise a sequence as set out in SEQ ID. NO: 27, 29, 31, 33, 69, 89, 91, 93, 95, 97, 146, 164, 165, 166, 167 or 185. A preferred KAH sequence is the polypeptide encoded by the nucleic acid set out in SEQ ID NO: 33.
[00124] A suitable recombinant microorganism can express a combination of the polypeptides encoded by SEQ ID NO: 85 and SEQ ID NO: 33 or a variant thereof as described herein. A preferred recombinant microorganism can express the combination of sequences set out in Table 8 (in combination with any UGT2, but in particular that encoded by SEQ ID NO: 87).
[00125] A nucleotide sequence encoding a UGT can, for example, comprise a sequence as set out in SEQ ID. NO: 35, 37, 39, 41, 43, 45, 47, 49, 51, 71, 73, 75, 16 8, 169, 170, 171, 172, 173, 174, 175, 176, 147, 148, 149 , 87, 181, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 , 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 189, 190, 191 or 192.
[00126] A nucleotide sequence encoding a hydroxymethylglutaryl-CoA reductase can, for example, comprise a sequence as set out in SEQ ID. NO: 79.
[00127] A nucleotide sequence encoding a farnesyl-pyrophosphate synthetase can, for example, comprise a sequence as set out in SEQ ID. NO: 81.
[00128] A nucleotide sequence encoding a geranylgeranyl diphosphate synthase can, for example, comprise a sequence as set out in SEQ ID. NO: 83.
[00129] A nucleotide sequence encoding a NADPH-cytochroma p450 reductase can, for example, comprise a sequence as set out in SEQ ID. NO: 53, 55, 57 or 77.
[00130] In the case of UGT sequences, combinations of at least one of each of: (i) SEQ ID NOs: 35, 37, 168, 169, 71, 147 or 189; (ii) SEQ ID NOs: 87, 99, 101, 103, 105, 107, 109, 111, 181 or 192; (iii) SEQ ID NOs: 39, 41, 43, 45, 47, 170, 171, 172, 173, 174, 73, 148 or 190; and (iv) SEQ ID NOs: 49, 51, 175, 176, 75, 149 or 191 may be preferred. Typically, at least one UGT from group (i) can be used. If at least one UGT from group (iii) is used, generally at least one UGT from group (i) is also used. If at least one UGT from group (iv) is used, generally at least one UGT from group (i) and at least one UGT from group (iii) is used. Typically, at least one UGT from group (ii) is used.
[00131] A sequence that is at least about 10%, about 15%, about 20%, preferably at least about 25%, about 30%, about 40%, about 50%, about 55 %, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97 %, about 98%, or about 99% sequence identity with a sequence as mentioned can be used in the invention.
[00132] To increase the probability that the introduced enzymes are expressed in the active form in a recombinant microorganism, the corresponding coding nucleotide sequence can be adapted to optimize its use of the codon to that of the chosen eukaryotic host cell. The adaptability of the nucleotide sequences that encode the enzymes to the use of the codon of the chosen host cell can be expressed as the codon adaptation index (CAI). The codon adaptation index is defined in this document as a measure of the relative adaptability of the use of the codon of a gene towards the use of the codon of highly expressed genes. The relative adaptability (w) of each codon is the reason for the use of each codon, to that of the most abundant codon for the same amino acid. The CAI index is defined as the geometric mean of these relative adaptability values. Non-synonymous codons and termination codons (dependent on the genetic code) are excluded. CAI values range from 0 to 1, with higher values indicating a greater proportion of the most abundant codons (see Sharp and Li, 1987, Nucleic Acids Research 15: 1281 - 1295; also see: Jansen et al., 2003, Nucleic Acids Res. 31 (8): 2242-51). An adapted nucleotide sequence preferably has a CAI of at least 0.2, 0.3, 0.4, 0.5, 0.6 or 0.7.
[00133] In a preferred embodiment, the recombinant is genetically modified with the nucleotide sequence (s) that are (are) adapted to the use of the eukaryotic cell codon using the codon pair optimization technology as described in PCT / EP2007 / 05594. Codon pair optimization is a method for producing a polypeptide in a host cell, in which the nucleotide sequences that encode the polypeptide have been modified with respect to its use of codon, in particular the codon pairs that are used for obtain improved expression of the nucleotide sequence encoding the polypeptide and / or improved production of the polypeptide. Codon pairs are defined as a set of two subsequent triplets (codons) in a coding sequence.
[00134] Further improvement of enzyme activity in vivo in a recombinant microorganism can be achieved by well-known methods such as error-prone PCR or directed evolution. A preferred method of directed evolution is described in WO03010183 and WO03010311.
[00135] A suitable recombinant microorganism can be any suitable host cell of microbial origin. Preferably, the host cell is a yeast or a filamentous fungus. More preferably, the host cell belongs to one of the genera Saccharomyces, Aspergillus, Penicillium, Pichia, Kluyveromyces, Yarrowia, Candida, Hansenula, Humicola, Torulaspora, Trichosporon, Brettanomyces, Pachysolen or Yamadazyma or Zygosaccharomyces.
[00136] A more preferred microorganism belongs to the species Aspergillus niger, Penicillium chrysogenum, Pichia stipidis, Kluyveromyces marxianus, K. lactis, K. thermotolerans, Yarrowia lipolitica, Candida sonorensis, C. glabrata, Hansenula polimorpha, Torulaspora brbraneckii , Zygosaccharomyces bailii, Saccharomyces uvarum, Saccharomyces bayanus or Saccharomyces cerevisiae species. Preferably, the eukaryotic cell is Saccharomyces cerevisiae.
[00137] A recombinant yeast cell can be modified so that the ERG9 gene is unregulated and / or the ERG5 / ERG6 genes are deleted. The corresponding genes can be modified in this way in other microorganisms.
[00138] Such a microorganism can be transformed, so the nucleotide sequence (s) with which the microorganism is transformed gives the cell (s) the ability to produce a diterpene or glycoside from them.
[00139] A preferred suitable recombinant microorganism is a yeast, such as a cell of Saccharomyces cerevisiae or Yarrowia lipolytic. A recombinant microorganism, such as a Saccharomyces cerevisiae recombinant cell or Yarrowia lipolytic cell can comprise one or more nucleotide sequence (s) from each of the following groups;
[00140] (i) SEQ ID. NO: 1, 3, 5, 7, 17, 19, 59, 61, 141, 142, 152, 153, 154, 159, 160, 182 or 184.
[00141] (ii) SEQ ID. NO: 9, 11, 13, 15, 17, 19, 63, 65, 143, 144, 155, 156, 157, 158, 159, 160, 183 or 184.
[00142] (iii) SEQ ID. NO: 21, 23, 25, 67 85, 145, 161, 162, 163, 180 or 186.
[00143] (iv) SEQ ID. NO: 27, 29, 31, 33, 69, 89, 91, 93, 95, 97, 146, 164, 165, 166, 167 or 185.
[00144] Such a microorganism will typically also comprise one or more nucleotide sequence (s) as set out in SEQ ID. NO: 53, 55, 57 or 77.
[00145] Such a microorganism may also comprise one or more nucleotide sequences as set out in 35, 37, 39, 41, 43, 45, 47, 49, 51, 71, 73, 75, 168, 169, 170, 171 , 172, 173, 174, 175, 176, 147, 148, 149, 87, 181, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113 , 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138 , 139, 140, 189, 190, 191 or 192. In the case of these sequences, combinations of at least one of each of (i) SEQ ID NOs: 35, 37, 168, 169, 71, 147 or 189; (ii) SEQ ID NOs: 87, 99, 101, 103, 105, 107, 109, 111, 181 or 192; (iii) SEQ ID NOs: 39, 41, 43, 45, 47, 170, 171, 172, 173, 174, 73, 148 or 190; and (iv) SEQ ID NOs: 49, 51, 175, 176, 75, 149 or 191 may be preferred. Typically, at least one UGT from group (i) can be used. If at least one UGT from group (iii) is used, generally at least one UGT from group (i) is also used. If at least one UGT from group (iv) is used, generally at least one UGT from group (i) and at least one UGT from group (iii) is used. Typically, at least one UGT from group (ii) is used.
[00146] Such a microorganism may also comprise the following nucleotide sequences: SEQ ID. NO: 79; SEQ ID. NO: 81; and SEQ ID. NO: 83.
[00147] For each sequence set out above (or any sequence mentioned in this document), a variant having at least about 15%, preferably at least about 20, about 25, about 30, about 40, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 96, about 97, about 98, or about 99% sequence identity to the given sequence can be used.
[00148] The nucleotide sequences encoding ent-copalyl pyrophosphate synthase, ent-kurene synthase, ent-kurene oxidase, kurenoic acid 13-hydroxylase, UGTs, hydroxymethylglutaryl-CoA reductase, farnesyl-pyrophosphate synthase, geranylgenylanthylate cytochrome p450 reductase can be linked to one or more nucleic acid constructs to facilitate the transformation of the microorganism.
[00149] A nucleic acid construct can be a plasmid that carries the genes encoding diterpene enzymes, for example, steviol / steviol glycoside, pathway as described above, or a nucleic acid construct can comprise two or three plasmids that they carry three or two genes, respectively, encoding the enzymes of the diterpene pathway distributed in any appropriate pathway.
[00150] Any suitable plasmid can be used, for example, a plasmid with a low copy number or a plasmid with a high copy number.
[00151] It may be possible that the enzymes selected from the group consisting of ent-copalyl pyrophosphate synthase, ent-kaurene synthase, ent-kaurene oxidase and kurenoic acid 13-hydroxylase, UGTs, hydroxymethylglutaryl-CoA reductase, farnesyl-pyrophosphate synthase, geranylgeran diphosphate synthase and NADPH-cytochroma p450 reductase are native to the host microorganism and that transformation with one or more of the nucleotide sequences encoding these enzymes cannot be required to give the host cell the ability to produce a diterpene or diterpene glycosidase . The further improvement in the production of diterpene / diterpene glycosidase by the host microorganism can be obtained by improving the classic strain.
[00152] The nucleic acid construct can be maintained episomically and thus comprise a sequence for autonomous replication, such as an autosomal replication sequence. If the host cell is of fungal origin, a suitable episomic nucleic acid construct can, for example, be based on yeast 2μ or pKD1 plasmids (Gleer et al., 1991, Biotechnology 9: 968-975) or AMA plasmids (Fierro et al., 1995, Curr Genet. 29: 482-489).
[00153] Alternatively, each nucleic acid construct can be integrated into one or more copies in the host cell genome. Integration into the host cell genome can occur randomly by non-homologous recombination, but preferably the nucleic acid construct can be integrated into the host cell genome by homologous recombination as is well known in the art (see, for example, WO90 / 14423, EP-A-0481008, EP-A-0635 574 and US 6,265,186).
[00154] Optionally, a selectable marker can be present in the nucleic acid construct. As used herein, the term "marker" refers to a gene that encodes a trait or phenotype that allows the selection of, or screening for, a microorganism containing the marker. The marker gene can be an antibiotic resistant gene so the appropriate antibiotic can be used to select transformed cells from cells that are not transformed. Alternatively or in the same way, markers without antibiotic resistance are used, such as auxotrophic markers (URA3, TRP1, LEU2). Host cells transformed with the nucleic acid constructs can be gene marker free. Methods for constructing microbial host cells free of recombinant gene marker are described in EP-A-0 635 574 and are based on the use of bidirectional markers. Alternatively, a screenable marker such as Fluorescent Green Protein, lacZ, luciferase, chloramphenicol acetyltransferase, beta-glucuronidase can be incorporated into the nucleic acid constructs allowing for screening of transformed cells. A preferred marker-free method for introducing heterologous polynucleotides is described in WO0540186.
[00155] In a preferred embodiment, the nucleotide sequences encoding ent-copalyl pyrophosphate synthase, ent-kaurene synthase, ent-kaurene oxidase and kaurenoic acid 13-hydroxylase, UGTs, hydroxymethylglutaryl-CoA reductase, farnesyl-pyrophosphate synthase, geranium synthase and NADPH-cytochroma p450 reductase are each operably linked to a promoter that causes sufficient expression of the corresponding nucleotide sequences in the recombinant microorganism to give the cell the ability to produce a glycoside diterpene or diterpene.
[00156] As used herein, the term "operably linked" refers to a bonding of polynucleotide elements (or coding sequences or nucleic acid sequence) in a functional relationship. A nucleic acid sequence is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
[00157] As used in this document, the term "promoter" refers to a fragment of nucleic acid that functions to control the transcription of one or more genes, located upstream with respect to the transcription direction of the gene transcription initiation site and is structurally identified by the presence of a DNA-dependent RNA polymerase binding site, transcription initiation sites and any other DNA sequences, including, but not limited to, transcription factor binding sites, repressor protein binding sites, and activator and any other nucleotide sequences known to someone skilled in the art to act directly or indirectly to regulate the amount of promoter transcription. A "constitutive" promoter is a promoter that is active under more environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or development regulation.
[00158] The promoter that could be used to achieve expression of the nucleotide sequences encoding an enzyme as defined herein above, may be native to the nucleotide sequence encoding the enzyme to be expressed, that is, a promoter that it is heterologous to the nucleotide sequence (coding sequence) to which it is operably linked. Preferably, the promoter is homologous, that is, endogenous to the host cell.
[00159] Promoters suitable for use in recombinant microorganisms can be GAL7, GAL10 or GAL 1, CYC1, HIS3, ADH1, PGL, PH05, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI, and AOX1. Other suitable promoters include PDC, GPD1, PGK1, TEF1 and TDH.
[00160] Any terminator, which is functional in the cell, can be used. Preferred terminators are obtained from natural host cell genes. Suitable terminator sequences are well known in the art. Preferably, such terminators are combined with mutations that prevent mRNA decay mediated by meaningless mutation in the host cell (see, for example: Shirley et al., 2002, Genetics 161: 1465-1482).
[00161] The nucleotide sequences used may include sequences that direct them to desired compartments of the microorganism. For example, in a preferred recombinant microorganism, all nucleotide sequences, except ent-kaurene oxidase, kaurenoic acid 13-hydroxylase and NADPH-cytochroma p450 reductase coding sequences can be targeted to the cytosol. This approach can be used in a yeast cell.
[00162] The term "homologous", when used to indicate the relationship between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, means that by nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, preferably of the same variety or strain.
[00163] The term "heterologous" when used with respect to a nucleic acid (DNA or RNA) or protein refers to a nucleic acid or protein that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present or found in a cell or location or locations in the genome or DNA or RNA sequence that differ from the one in which it is found in nature. The heterologous nucleic acids or proteins are not endogenous to the cell in which they are introduced, but have been obtained from another cell or produced synthetically or recombinantly.
[00164] Typically, a suitable recombinant microorganism will comprise heterologous nucleotide sequences. Alternatively, a recombinant microorganism may comprise the fully homologous sequence that has been modified as set forth herein so that the microorganism produces increased amounts of a diterpene and / or diterpene glycoside compared to an unmodified version of the same microorganism.
[00165] One or more enzymes in the diterpene pathway as described in this document can be overexpressed to achieve sufficient production of diterpene by the cell.
[00166] There are several means available in the art for the overexpression of enzymes in the host cell. In particular, an enzyme can be overexpressed by increasing the number of copies of the gene encoding the enzyme in the host cell, for example, by integrating additional copies of the gene into the host cell's genome.
[00167] A preferred recombinant microorganism can be a recombinant microorganism that is naturally capable of producing GGPP.
[00168] A suitable recombinant microorganism may be able to grow on any suitable carbon source known in the art and convert it to one or more steviol glycosides. The recombinant microorganism may be able to directly convert plant biomass, celluloses, hemicelluloses, pectins, rhamnose, galactose, fucose, maltose, maltodextrins, ribose, ribulose or starch, derivatives of starch, sucrose, lactose and glycerol. Consequently, a preferred host organism expresses enzymes such as cellulases (endocellulases and exocellulases) and hemicellulases (eg, endo- and exoxylanases, arabinases) necessary for the conversion of cellulose into glucose and hemicellulose monomers in xylose and arabinose monomers, pectinases capable of converting pectins to glucuronic acid and galacturonic acid or amylases to convert starch into glucose monomers. Preferably, the host cell is capable of converting a carbon source selected from the group consisting of glucose, xylose, arabinose, sucrose, lactose and glycerol. The host cell can, for example, be a eukaryotic host cell as described in WO03 / 062430, WO06 / 009434, EP1499708B1, WO2006096130 or WO04 / 099381.
[00169] A recombinant microorganism as described above can be used in a process for the production of a steviol glycoside, the method of which involves fermenting a suitable transformed recombinant microorganism (as described in this document) in a fermentation medium appropriate and optionally the recovery of the diterpene and / or diterpene glycoside.
[00170] The fermentation medium used in the process for the production of a glyceride diterpene or diterpene can be any suitable fermentation medium that allows the growth of a particular eukaryotic host cell. The essential elements of the fermentation medium are known to a person skilled in the art and can be adapted to the selected host cell.
[00171] Preferably, the fermentation medium comprises a carbon source selected from the group consisting of plant biomass, celluloses, hemicelluloses, pectins, rhamnose, galactose, fucose, maltose, maltodextrins, ribose, ribulose or starch, starch derivatives, sucrose , lactose, fatty acids, triglycerides and glycerol. Preferably, the fermentation medium also comprises a nitrogen source such as urea or an ammonium salt such as ammonium sulfate, ammonium chloride, ammonium nitrate or ammonium phosphate.
[00172] A suitable fermentation process can be carried out in batch, batch-fed or continuous mode. A separate hydrolysis and fermentation process (SHF) or a simultaneous saccharification and fermentation process (SSF) can also be applied. A combination of these fermentation process modes may also be possible for optimal productivity. An SSF process can be particularly attractive if starch, cellulose, hemicellulose or pectin are used as a carbon source in the fermentation process, where it may be necessary to add hydrolytic enzymes, such as cellulases, hemicellulases or pectinases to hydrolyze the substrate.
[00173] The recombinant microorganism used in the process for the preparation of a steviol glycoside can be any suitable microorganism as defined in this document above. It may be advantageous to use a recombinant eukaryotic microorganism as described in this document in the process for the production of a diterpene or diterpene glycoside, because most eukaryotic cells do not require sterile conditions for propagation and are insensitive to bacteriophage infections. In addition, eukaryotic host cells can be developed at low pH to prevent bacterial contamination.
[00174] The recombinant microorganism can be an optional anaerobic microorganism. An optional anaerobic microorganism can be propagated aerobically in a high cell concentration. This anaerobic phase can then be performed at high cell density which reduces the required fermentation volume substantially and can minimize the risk of contamination with aerobic microorganisms.
[00175] The fermentation process for the production of a steviol glycoside can be an aerobic or anaerobic fermentation process.
[00176] An anaerobic fermentation process may be defined herein as an execution of the fermentation process in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than 5, 2.5 or 1 mmol / L / h in that organic molecules serve as both electron donors and electron acceptors. The fermentation process can also be performed first under aerobic conditions and subsequently under anaerobic conditions.
[00177] The fermentation process can also be performed under oxygen-limited or microaerobic conditions. Alternatively, the fermentation process can be performed first under aerobic conditions and subsequently under oxygen-limited conditions. An oxygen-bound fermentation process is a process in which oxygen consumption is limited by the transfer of oxygen from gas to liquid. The degree of oxygen limitation is determined by the amount and composition of the incoming gas flow as well as the current mass / mix transfer properties of the fermentation equipment used.
[00178] The production of a steviol glycoside in the fermentation process can occur during the growth phase of the host cell, during the stationary phase (constant state) or during both phases. It may be possible to carry out the fermentation process at different temperatures.
[00179] The process for producing a steviol glycoside can be performed at a temperature that is ideal for the recombinant microorganism. The ideal growth temperature may differ for each transformed cell and is known to the person skilled in the art. The ideal temperature can be higher than the ideal for wild type organisms to develop the organism efficiently under non-sterile conditions under sensitivity to minimal infection and lower cooling cost. Alternatively, the process can be carried out at a temperature that is not ideal for the growth of the recombinant microorganism.
[00180] The temperature for the growth of the recombinant microorganism in a process for the production of a diterpene or diterpene glycoside can be above 20 ° C, 22 ° C, 25 ° C, 28 ° C or above 30 ° C, 35 ° C or above 37 ° C, 40 ° C, 42 ° C and preferably below 45 ° C. During the production phase of a glyceride diterpene or diterpene, however, the ideal temperature must be lower than the average in order to optimize the stability of the biomass. The temperature during this phase can be below 45 ° C, for example, below 42 ° C, 40 ° C, 37 ° C, for example, below 35 ° C, 30 ° C or below 28 ° C, 25 ° C, 22 ° C or below 20 ° C preferably above 15 ° C.
[00181] The process for producing a steviol glycoside can be carried out at any suitable pH value. If the recombinant microorganism is yeast, the pH in the fermentation medium preferably has a value below 6, preferably below 5.5, preferably below 5, preferably below 4.5, preferably below 4, preferably below pH 3.5 or below pH 3.0 or below pH 2.5, preferably above pH 2. An advantage of carrying out fermentation at these low pH values is that the growth of contaminating bacteria in the fermentation medium can be avoided .
[00182] Such a process can be performed on an industrial scale.
[00183] The product of such a process may be one or more of steviolmonoside, steviolbioside, stevioside or rebaudioside A, rebaudioside B, rebaudioside C, rebaudioside D, rebaudioside E, rebaudioside F, rubusoside, dulcoside A. Preferably, rebaudioside A or rebaudioside A or rebaudioside A or Is Produced.
[00184] The recovery of the diterpene or diterpene glycoside from the resulting broth can be carried out according to the invention.
[00185] In the process for the fermentative production of a steviol glycoside, it may be possible to achieve a concentration of above 5 mg / l of the fermentation broth, preferably above 10 mg / l, preferably above 20 mg / l, preferably above 30 mg / l of fermentation broth, preferably above 40 mg / l, more preferably above 50 mg / l, preferably above 60 mg / l, preferably above 70, preferably above 80 mg / l, preferably above 100 mg / l, preferably above 1 g / l, preferably above 5 g / l, preferably above 10 g / l, but generally below 70 g / l in the broth.
[00186] As described above, in the event that a diterpene or diterpene glycoside is expressed within the microorganism, such cells may need to be treated in order to release the steviol glycoside.
[00187] The solution and / or composition according to the invention can be used in any known application for steviol glycosides. In particular, they can, for example, be used as a sweetener, for example, in a food or drink. For example, steviol glycosides can be formulated into soft drinks, such as a table sweetener, chewing gum, dairy product such as yogurt (for example, plain yogurt), pie, cereal or cereal-based foods, nutraceutical products, pharmaceuticals , edible gel, confectionery, cosmetics, toothpastes or other compositions for the oral cavity, etc. In addition, a steviol glycoside can be used as a sweetener not only for drinks, foodstuffs and other products dedicated to human consumption, but also in animal feed and forage with improved characteristics.
[00188] During the manufacture of foodstuffs, beverages, pharmaceuticals, cosmetics, tableware, chewing gum, conventional methods such as mixing, kneading, dissolving, pickling, permeation, percolation, spraying, atomization, infusion and other methods can be used.
[00189] The solution and / or composition obtained in this invention can be used in dry or liquid forms. It can be added before or after heat treatment of food products. The amount of the sweetener depends on the purpose of use. It can be added alone or in combination with other compounds.
[00190] Solutions and compositions produced according to the recovery method of the invention can be mixed with one or more additional non-calorific or calorific sweeteners. Such a mixture can be used to improve flavor or profile or temporal stability. A wide range of both non-calorific and calorific sweeteners may be suitable for mixing with steviol glycosides. For example, non-calorific sweeteners such as mogroside, monatin, aspartame, acesulfame salts, cyclamate, sucralose, saccharine salts or erythritol. Calorific sweeteners suitable for mixing with the sweetening composition include sugar alcohols and carbohydrates such as sucrose, glucose, fructose and HFCS. Sweet-tasting amino acids, such as glycine, alanine or serine, can also be used.
[00191] Steviol glycoside can be used in combination with a sweetener suppressor, such as a natural sweetener suppressant. It can be combined with an umami taste enhancer, such as an amino acid or a salt thereof.
[00192] A steviol glycoside can be combined with a polyol or sugar alcohol, a carbohydrate, a physiologically active substance or functional ingredient, for example, a carotenoid, dietary fiber, fatty acid, saponin, antioxidant, nutraceutical, flavonoid, isothiocyanate , phenol, plant sterol or stanol (phytosterols and phytostanols), a polyol, a prebiotic, a probiotic, a phytoestrogen, soy protein, sulfides / thiols, amino acids, a protein, a vitamin, a mineral and / or a classified substance based on health benefits, such as cardiovascular, cholesterol-lowering or anti-inflammatory benefits.
[00193] A composition or solution according to the invention can include a flavoring agent, a flavor component, a nucleotide, an organic acid, an organic acid salt, an inorganic acid, a bitter compound, a protein or protein hydrolyzate , a surfactant, a flavonoid, an adseverae compound, a vitamin, a dietary fiber, an antioxidant, a fatty acid and / or a salt.
[00194] A composition or solution of the invention can be applied as a high intensity sweetener to produce drinks with zero calorie, reduced calorie or for diabetics and food products with improved flavor characteristics. Likewise, it can be used in drinks, foodstuffs, pharmaceuticals and other products in which sugar cannot be used.
[00195] In addition, a composition or solution of the invention can be used as a sweetener not only for drinks, foodstuffs and other products dedicated to human consumption, but also in animal feed and forage with improved characteristics.
[00196] Examples of products, where a composition or solution of the invention can be used as a sweetening compound, can be as alcoholic beverages, such as vodka, wine, beer, liquor, sake, etc., natural juices, refreshing drinks, soft drinks carbonated drinks, diet drinks, zero calorie drinks, low calorie drinks and foods, alcoholic drinks with yogurt, instant juices, instant coffee, powder types of instant drinks, canned products, syrups, fermented soy paste, soy sauce, vinegar, sauces, mayonnaise, ketchup, curry, soup, instant broth, powdered soy sauce, powdered vinegar, types of cookies, rice cracker, crackers, bread, chocolates, caramel, sweets, chewing gum, jam, pudding , canned fruits and vegetables, fresh cream, jam, marmalade, flower paste, powdered milk, ice cream, ice cream, fruits and vegetables packaged in bottles, canned and cooked beans, meat and food cooked in a sweet sauce, organic products agricultural vegetables, seafood, ham, sausage, fish meat ham, fish sausage, fish paste, deep-fried fish products, fried sea food products, frozen food products, preserved seaweed, canned meat, tobacco, medicinal products and many others. In the beginning, they can have unlimited applications.
[00197] The sweetened composition comprises a drink, the non-limiting examples of which include carbonated and non-carbonated drinks such as colas, ginger beers, root beers, ciders, fruit flavored soft drinks (e.g. citrus flavored soft drinks such as lime) lemon or orange), powdered soft drinks and the like; fruit juices originating from fruits or vegetables, fruit juices including squeezed juices or the like, fruit juices containing fruit particles, fruit drinks, fruit juice drinks, fruit juice drinks, fruit flavored drinks , vegetable juices, vegetable juices and mixed juices containing fruits and vegetables; sports drinks, energy drinks, near water and similar drinks (for example, water with natural or synthetic flavorings); tea-type or favorite-type drinks such as coffee, cocoa, black tea, green tea, oolong tea and the like; drinks containing milk components such as milk drinks, coffee containing milk components, coffee with milk, tea with milk, fruit and milk drinks, yogurt to drink, drinks with lactic acid bacteria or the like; and dairy products.
[00198] Generally, the amount of sweetener present in a sweetened composition varies widely depending on the particular type of sweetened composition and its desired sweetness. Those skilled in the art can readily discern the appropriate amount of sweetener to add to the sweetened composition.
[00199] The composition or solution of the invention obtained as described in this document can be used in dry or liquid forms. It can be added before or after heat treatment of food products. The amount of the sweetener depends on the purpose of use. It can be added alone or in combination with other compounds.
[00200] During the manufacture of foodstuffs, beverages, pharmaceuticals, cosmetics, tableware, chewing gum, conventional methods such as mixing, kneading, dissolving, pickling, permeation, percolation, spraying, atomization, infusion and other methods can be used.
[00201] In solid form, a composition of the present invention can be provided to consumers in any form suitable for distribution to the edible product to be sweetened, including sachets, packages, bags or boxes as a bulk, cubes, tablets, mists or strips dissolvable. The composition can be delivered as a unit dose or in bulk.
[00202] For liquid sweetener systems and compositions, convenient ranges of fluid, semifluid, paste and cream forms, appropriate packaging using appropriate packaging material in any shape or form should be invented that are convenient to carry or dispense or store or transport any combination containing any of the above sweetener products or combination of products produced above.
[00203] The composition or solution of the invention can include various bulking agents, functional ingredients, coloring, flavoring.
[00204] A reference here to a patent document or other matter that is given as a prior art should not be considered an admission that that document or matter was known or that the information it contains was part of common general knowledge as at the date priority of any of the claims.
[00205] The description of each reference established here is incorporated here by reference in its entirety.
[00206] The present invention is further illustrated by the following Examples: Examples General
[00207] Standard genetic techniques, such as overexpression of enzymes in host cells, as well as for additional genetic modification of host cells, are methods known in the art, such as described in Sambrook and Russel (2001) "Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, or F. Ausubel et al, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987). the genetic transformation and modification of fungal host cells are known from, for example, EP-A-0 635 574, WO 98/46772, WO 99/60102 and WO 00/37671.
[00208] A description of the sequences is established in Table 1. The sequences described in this document can be defined with reference to the sequence listing or with reference to the database access numbers also established in Table 1. Example 1. Overexpression of ERG20, BTS1 and tHMG in S. cerevisiae
[00209] For the overexpression of ERG20, BTS1 tHMG1, expression cassettes were designed to be integrated in one location using the technology described in copending patent application no. PCT / EP2013 / 056623. To amplify the 5 'and 3' integration flanks for the integration site, suitable primers and genomic DNA from a CEN.PK yeast strain (van Dijken et al. Enzyme and Microbial Technology 26 (2000) 706-714) were used . The different genes were ordered as cassettes (containing homologous sequence, promoter, gene, terminator, homologous sequence) in DNA2.0. The genes in these cassettes were flanked by constitutive promoters and terminators. See Table 2. The DNA2.0 plasmid DNA containing the ERG20, tHMG1 and BTS1 cassettes were dissolved at a concentration of 100 ng / μl. In a 50 μl PCR mixture, 20 ng of the template was used with 20 pmols of primers. The material was dissolved at a concentration of 0.5 μg / μl. Table 2: Composition of the overexpression constructs.
For amplification of the selection marker, the pUG7-EcoRV construct (Figure 1) and suitable primers were used. The KanMX fragment was gel purified using the Zymoclean Gel DNA recovery kit (ZymoResearch). The Cen.PK1 13-3C yeast strain was transformed with the fragments listed in Table 3. Table 3: DNA fragments used for the transformation of ERG20, tHMGl and BTS1

[00210] After transformation and recovery for 2.5 hours in YEPhD (yeast extract phyton peptone glucose; BBL Fitone Peptone from BD) at 30 ° C, the cells were plated on YEPhD agar with 200 μg / ml G418 (Sigma) . The plates were incubated at 30 ° C for 4 days. Correct integration was established with diagnostic PCR and sequencing. Overexpression was confirmed with LC / MS in the proteins. The assembly diagram for ERG20, tHMG1 and BTS1 is illustrated in Figure 2. This strain is named STV002.
[00211] CRE-recombinase expression in this strain led to external recombination of the KanMX marker. Correct external recombination and the presence of ERG20, tHMG and BTS1 was established with diagnostic PCR. Example 2. Reduction of Erg9 expression
[00212] To reduce Erg9 expression, an Erg9 expression reduction construct was designed and used that contains a modified 3 'end, which continues inside the TRP1 promoter by triggering TRP1 expression.
[00213] The construct containing the Erg9-KD fragment was transformed into E. coli TOP10 cells. The transformants were developed in 2PY (2 times of yeast extract phyton peptone), sAMP medium. Plasmid DNA was isolated with the QIAprep Spin Miniprep kit (Qiagen) and digested with Sall-HF (New England Biolabs). To concentrate, the DNA was precipitated with ethanol. The fragment was transformed into S. cerevisiae and the colonies were plated on agar plates in mineral medium (Verduyn et al, 1992. Yeast 8: 501-517) without tryptophan. The correct integration of the Erg9-KD construct was confirmed with diagnostic PCR and sequencing. The transformation scheme carried out for the Erg9-KD construct is illustrated in Figure 3. The strain was named STV003. Example 3. UGT2 1a overexpression
[00214] For the overexpression of UGT2_1a, the technology was used as described in copendent patent applications nos. PCT / EP2013 / 056623 and PCT / EP2013 / 055047. UGT2_1a was ordered as a cassette (containing homologous sequence, promoter, gene, terminator, homologous sequence) in DNA2.0. for details, see Table 4. To obtain fragments containing the marker and Cre-recombinase, the technology was used as described in copending patent application no. PCT / EP2013 / 055047. The NAT marker, which confers resistance to nourseotricin, was used for the selection. Table 4: Composition of the overexpression construct

[00215] Suitable primers were used for amplification. To amplify the 5 'and 3' integration flanks for the integration site, suitable primers and genomic DNA from a CEN.PK yeast strain were used.
[00216] The yeast strain of S. cerevisiae STV003 was transformed with the fragments listed in Table 5 and the transformation mixture was plated on YEPhD agar plates containing 50 μg / ml of nourseotricin (Lexy NTC from Jena Bioscience). Table 5: DNA fragments used for the transformation of UGT2_1a

[00217] CRE recombinase expression is activated by the presence of galactose. To induce the expression of CRE recombinase, the transformants were seeded again in YEPh Galactose medium. This resulted in external recombination of the marker (s) located between the lox sites. The correct integration of UGT2a and the external recombination of the NAT marker was confirmed with diagnostic PCR. The resulting strain was named STV004. The schematic of the transformation carried out for the UGT2_1a construct is illustrated in Figure 4. Example 4. Overexpression of the production path for RebA: CPS, KS, KO, KAH, CPR, UGT1, UGT3 and UGT4.
[00218] All genes in the pathway leading to the production of RebA were designed to be integrated into one location using the technology described in copending patent application no. PCT / EP2013 / 056623. To amplify the 5 'and 3' integration flanks for the integration site, suitable primers and genomic DNA from a CEN.PK yeast strain were used. The different genes were ordered as cassettes (containing homologous sequence, promoter, gene, terminator, homologous sequence) in DNA2.0 (see Table 5 for an overview). DNA2.0 DNA was dissolved at 100 ng / μl. This stock solution was further diluted to 5 ng / μl, of which 1 μl was used in a 50μl PCR mixture. The reaction contained 25 pmols of each primer. After amplification, the DNA was purified with the NucleoSpin 96 PCR Clean-up kit (Macherey-Nagel) or alternatively concentrated using ethanol precipitation. Table 6. Sequences used for the production path for RebA


[00219] All fragments for the path to RebA, the marker and the flanks (see the overview in Table 7) were transformed into a yeast strain S. cerevisiae STV004. After overnight recovery in YEPhD at 20 ° C, the transformation mixture was plated on YEPhD agar containing 200 μg / ml of G418. These were incubated 3 days at 25 ° C and overnight at RT. Table 7. DNA fragments used for the transformation of CPS, KS, KO, KanMX, KAH, CPR, UGT1, UGT3 and UGT4.

[00220] The correct integration was confirmed with diagnostic PCR and analysis of a sequence (3500 Genetic Analyzer, Applied Biosystems). The reactions of a sequence were made with the BigDye Terminator v3.1 Cycle Sequencing kit (Life Technologies). Each reaction (10 μl) contained 50 ng of mold and 3.2 pmols of initiator. The products were purified by ethanol / EDTA precipitation, dissolved in 10 μl of HiDi formamide and applied to the apparatus. The strain was named STV016. The outline of how the GGPP pathway to RebA is integrated into the genome is illustrated in Figure 5. Example 5: Construction of STV027 strain
[00221] To remove the KanMX marker from the chromosome of the STV016 strain, this strain was transformed with plasmid pSH65, expressing Cre-recombinase (Guldender, 2002). Subsequently, plasmid pSH65 was cured of the strain by development in the non-selective medium (YEP 2% glucose). The resulting strains free of KanMX and free of pSH65, as determined by plating on plates containing 200 μg of G418 / ml or 20 μg of phleomycin / ml, where no growth should occur, were named STV027. The absence of the KanMX marker was also confirmed with diagnostic PCR. Example 6: STV027 strain fermentation
[00222] The yeast strain STV027 constructed as described above was grown in a shaking flask (500 ml medium with 50 ml) for 2 dichas at 30 ° C and 280 rpm. The medium was based on Verduyn et al. (Verduyn C, Postma E, Scheffers WA, Van Dijken JP. Yeast, 1992 Jul; 8 (7): 501 - 517), with modifications in the sources of carbon and nitrogen, as described in Table 8. Table 8. Composition of the medium pre-culture
Trace element solution 1
bVitamin solution


[00223] Subsequently, 6 ml of the contents of the shake flask were transferred into a fermenter (initial volume of 0.3 L), which contained the medium as set out in Table 9. Table 9. Composition fermentation medium

[00224] The pH was controlled at 5.0 by the addition of ammonia (12.5% by weight). The temperature was controlled at 27 ° C. pO2 was controlled at 40% by adjusting the agitator speed. The glucose concentration was kept limited by the controlled feed to the fermenter. Table 10. Composition of fermentation feed medium
Example 7: Chromatography
[00225] The S. cerevisiae STV027 strain fermentation broth suffered a heat shock (1 h at 90 ° C) and was spray dried. Reb A was extracted with ethanol (1st extraction: 1 kg of powder with 8 L of 90% EtOH, 65 ° C, contact time 3 h; after filtration, the cake was extracted again with 8 L of EtOH at 90 % at 65 ° C, contact time 2h, 1st and 2nd extracts were combined). This extract was subjected to a 2-stage chromatography process to remove other components. In Table 11, the execution parameters are displayed. Table 11: Chromatography parameters


[00226] The column was loaded with the amount of extract that corresponds to 500 mg of Reb A in a 20% EtOH solution, the pH remained as such. The column was washed with 20 column volumes (CV) of 20% EtOH to wash unbound components. Subsequently, an ethanol gradient of 20% to 100% Buffer B at 18.2 CV was applied to elute Reb A. The elution pattern is known in Figure 6. Table 12 establishes relative quantities (expressed in%) in different fractions of the chromatographic execution: washing, elution and fractions 1 to 6. The initial concentration of the respective compounds is taken as 100%. Table 12. Step Performance Experiment


[00227] After the first purification, the elution fractions were combined and diluted in 20% ethanol concentration. The pH of this solution is then adjusted to 8.5 using 0.1 M NaOH. This solution is used as a feed. The elution pattern is shown in Figure 7. Table 13 then establishes relative amounts (expressed in%) in different fractions of the chromatographic run: washing, elution and fractions 1 to 6. The initial concentration of the respective compounds is taken as 100%. Table 13: Stage Yield Experiment


[00228] Table 14 shows the purity of RebA as% in the total dry material. The raw material contained 2.3% and the final chromatography fractions ended at around 30%. That is, a 15-fold purification of rebA. Table 14: Purification of RebA
Table 1: Description of the Sequence Listing









Shaded identities are truncated and thus a fragment of the mentioned UniProt identity.

权利要求:
Claims (15)
[0001]
1. Process for the recovery of one or more steviol glycosides from a fermentation broth containing steviol glycoside, the process characterized by comprising: (a) provision of a fermentation broth containing steviol glycoside and a solvent; (b) provision of an adsorbent resin; (c) provision of an eluting solvent; (d) contacting the adsorbent resin with the liquid phase or broth and eluting solvent, so that a portion or all components of non-steviosis glycosides adsorb on the adsorbent, enriching the glycoside solution in steviol glycosides and resulting in the formation of a composition of purified steviol glycoside which is eluted from the adsorbent together with the eluting solvent; and (e) optionally, desorbing the non-steviol glycoside components from the adsorbent, and thereby, to recover one or more steviol glycosides from the fermentation broth containing one or more steviol glycosides, wherein the eluting solvent comprises 50 % by weight or less of ethanol; and 50% by weight or more of water; and wherein the adsorbent resin is a polystyrene-divinylbenzene resin.
[0002]
2. Process according to claim 1, characterized by the fact that the adsorbent resin is provided in a filling column in an expanded bed mode.
[0003]
Process for recovering one or more steviol glycosides from a fermentation broth containing steviol glycoside according to claim 1, the process comprising: (a) providing a fermentation broth comprising one or more glycosides steviol and one or more non-steviol glycoside components and a solvent; (b) separating a liquid phase of the broth from a solid phase of the broth; (c) provision of an adsorbent resin; (d) providing an eluting solvent; (e) contact of the adsorbent resin with the liquid phase or elution broth and solvent, so that a portion or all components of non-steviol glycosides adsorb on the adsorbent, enriching the solution of glycosides in steviol glycosides and resulting in the formation of a purified steviol glycoside composition that is eluted from the adsorbent together with the eluting solvent; and (f) optionally, desorption of the non-steviol glycoside components of the adsorbent.
[0004]
4. Process according to claim 3, characterized by the fact that the adsorbent resin is provided in a filling column.
[0005]
Process according to any one of claims 1 to 4, characterized in that the eluting solvent comprises 20% by weight or less of ethanol; and 80% by weight or more of water.
[0006]
6. Process according to any one of claims 1 to 5, characterized by the fact that the separation method comprises fractionation chromatography.
[0007]
7. Process according to claim 6, characterized by the fact that fractionation chromatography comprises the steps of: (a) provision of a liquid phase, as defined in claim 3 (b) or a broth, as defined in claim 1 (a), and a solvent; (b) provision of an adsorbent and; (c) contacting the adsorbent with the liquid phase or broth so that part or all of the non-steviol glycoside components adsorb on the adsorbent and so that at least a part of the steviol glycoside adsorbes on the adsorbent, where the glycosides steviol propagate through the adsorbent at a faster rate than non-steviol glycosides; (d) collecting a solution containing steviol glycoside from the adsorbent.
[0008]
8. Process according to claim 7, characterized by the fact that the adsorbent is provided in a filling column.
[0009]
Process according to claim 7 or 8, characterized in that the solvent comprises 20% by weight or more of ethanol and 80% by weight or less of water.
[0010]
10. Process according to claim 9, characterized by the fact that the solvent comprises 25% to 35% by weight of ethanol and 65% to 75% of water.
[0011]
11. Process according to claim 7 or 8, characterized by the fact that the solvent comprises water and in which the adsorbent is a strongly acidic cation exchange resin.
[0012]
12. Process according to any one of claims 1 to 11, characterized in that the adsorbent has a surface area of 900 m2 / gram or greater.
[0013]
13. Process according to any one of the preceding claims, characterized by the fact that the solution containing recovered steviol glycoside has a purity that is 10% or above 10%, greater when compared to a liquid phase purity, as defined in claim 3 (b), or broth, as defined in claim 1 (a).
[0014]
Process according to any one of claims 1 to 13, characterized in that the solution containing purified steviol glycoside comprises, on a dry solids basis, 95% or above 95%, greater in weight than Rebaudioside A, Rebaudioside D or Rebaudioside M.
[0015]
Process according to any one of claims 1 to 14, characterized in that the solution containing steviol glycoside is spray dried to provide a powder.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US11117916B2|2021-09-14|Recovery of steviol glycosides

---

US20200283815A1|2020-09-10|Microorganisms for diterpene production

---

AU2014292150B2|2019-04-04|Diterpene production

---

US10273519B2|2019-04-30|Diterpene production in Yarrowia

---

US20180073050A1|2018-03-15|Extracellular diterpene production

---

DK2806754T3|2019-02-18|Diterpene PREPARATION

同族专利:

---

公开号 | 公开日

---

US10689410B2|2020-06-23|

---

AU2014298420A1|2016-02-04|

---

CA2917699A1|2015-02-05|

---

WO2015014959A1|2015-02-05|

---

US11117916B2|2021-09-14|

---

MX369591B|2019-11-13|

---

DK3027632T3|2019-06-17|

---

US20160185813A1|2016-06-30|

---

EP3027632A1|2016-06-08|

---

MX2016001003A|2016-05-09|

---

EP3027632B1|2019-03-20|

---

CN108064226A|2018-05-22|

---

EP3536697A1|2019-09-11|

---

CA2917699C|2021-12-07|

---

AU2014298420B2|2018-10-04|

---

US20200361979A1|2020-11-19|

---

US20180222935A1|2018-08-09|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

WO1990014423A1|1989-05-18|1990-11-29|The Infergene Company|Microorganism transformation|

---

DE69031710T2|1989-07-07|1998-03-05|Unilever Nv|METHOD FOR PRODUCING A PROTEIN BY MEANS OF A MUSHROOM TRANSFORMED BY MULTIPLE COPY INTEGRATION OF AN EXPRESSION VECTOR|

---

DE69432543T2|1993-07-23|2003-12-24|Dsm Nv|Selection marker gene-free recombinant strains: process for their preparation and the use of these strains|

---

US6265186B1|1997-04-11|2001-07-24|Dsm N.V.|Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces|

---

PL336345A1|1997-04-11|2000-06-19|Dsm Nv|Genic conversion as a tool for constructing recombined filiform fungi|

---

ID27054A|1998-05-19|2001-02-22|Dsm Nv|IMPROVING THE PRODUCTION OF SEPALOSPORIN IN LIVING ORGANISMS|

---

WO2000037671A2|1998-12-22|2000-06-29|Dsm N.V.|Improved in vivo production of cephalosporins|

---

AT321850T|2001-07-23|2006-04-15|Dsm Ip Assets Bv|METHOD FOR PRODUCING POLYNUCLEOTIVARIANTS|

---

AU2002333269A1|2001-07-23|2003-02-17|Dsm Ip Assets B.V.|Process for preparing variant polynucleotides|

---

CA2474033C|2002-01-23|2013-06-04|Royal Nedalco B.V.|Fermentation of pentose sugars|

---

SE0202090D0|2002-05-08|2002-07-04|Forskarpatent I Syd Ab|A modified yeast consuming L-arabinose|

---

AU2004236724B2|2003-05-02|2008-07-10|Cargill Inc.|Genetically modified yeast species and fermentation processes using genetically modified yeast|

---

US20070298455A1|2003-10-14|2007-12-27|Van Den Berg Marco A|Method For Preparing A Modified Host Cell|

---

DK1781772T3|2004-07-16|2017-01-09|Dsm Ip Assets Bv|Metabolic MODIFICATION of xylose-fermenting eukaryotic cells|

---

EP1863901A1|2005-03-11|2007-12-12|Forskarpatent i Syd AB|Arabinose- and xylose-fermenting saccharomyces cerevisiae strains|

---

CN101003552A|2006-01-18|2007-07-25|广西师范大学|Method for preparing glycosides in high purity|

---

WO2009140394A1|2008-05-13|2009-11-19|Cargill, Incorporated|Separation of rebaudioside a from stevia glycosides using chromatography|

---

CN101701238B|2009-10-14|2011-11-16|南京师范大学|Method for preparing rubusoside by stevioside|

---

RU2596190C9|2009-10-15|2016-10-20|ПЬЮСЁРКЛ ЭсДиЭн БиЭйчДи|Rebaudioside d of high purity and use thereof|

---

CN101691389B|2009-10-16|2011-11-16|南京师范大学|Method for improving sweetness of stevia sugar|

---

NZ604915A|2010-06-02|2014-10-31|Evolva Nutrition Inc|Recombinant production of steviol glycosides|

---

CN102295668B|2010-12-03|2014-04-02|恩施清江生物工程有限公司|Method for preparing high-purity steviosides from stevia|

---

WO2013110673A1|2012-01-23|2013-08-01|Dsm Ip Assets B.V.|Diterpene production|

---

AU2014214004B2|2013-02-06|2018-05-24|Evolva Sa|Methods for improved production of Rebaudioside D and Rebaudioside M|US10696706B2|2010-03-12|2020-06-30|Purecircle Usa Inc.|Methods of preparing steviol glycosides and uses of the same|

---

NZ604915A|2010-06-02|2014-10-31|Evolva Nutrition Inc|Recombinant production of steviol glycosides|

---

SG10201606563PA|2011-08-08|2016-10-28|Evolva Sa|Recombinant production of steviol glycosides|

---

AU2014214004B2|2013-02-06|2018-05-24|Evolva Sa|Methods for improved production of Rebaudioside D and Rebaudioside M|

---

SG11201506127WA|2013-02-11|2015-09-29|Evolva Sa|Efficient production of steviol glycosides in recombinant hosts|

---

AU2015303294A1|2014-08-11|2017-02-02|Evolva Sa.|Production of steviol glycosides in recombinant hosts|

---

JP2017528134A|2014-09-09|2017-09-28|エヴォルヴァ エスアー．Ｅｖｏｌｖａ Ｓａ．|Production of steviol glycosides in recombinant hosts|

---

CA2973674A1|2015-01-30|2016-08-04|Evolva Sa|Production of steviol glycosides in recombinant hosts|

---

CA2979931A1|2015-03-16|2016-09-22|Dsm Ip Assets B.V.|Udp-glycosyltransferases|

---

WO2016196368A1|2015-05-29|2016-12-08|Cargill, Incorporated|Fermentation methods for producing steviol glycosides with multi-phase feeding|

---

CN107949632B|2015-05-29|2021-06-01|嘉吉公司|Fermentation process for the production of steviol glycosides using high pH and compositions obtained thereby|

---

US10612065B2|2015-05-29|2020-04-07|Cargill, Incorporated|Heat treatment to produce glycosides|

---

EP3331373A4|2015-08-06|2019-07-10|Cargill, Incorporated|Fermentation methods for producing steviol glycosides|

---

BR112018002564A2|2015-08-07|2018-09-25|Evolva Sa|production of steviol glycosides in recombinant hosts|

---

CA3007726A1|2015-12-10|2017-06-15|Evolva Sa|Production of steviol glycosides in recombinant hosts|

---

CA3020671A1|2016-04-13|2017-10-19|Evolva Sa|Production of steviol glycosides in recombinant hosts|

---

EP3458599A1|2016-05-16|2019-03-27|Evolva SA|Production of steviol glycosides in recombinant hosts|

---

RU2019104496A3|2016-08-12|2021-04-09|

---

JP2020533954A|2017-08-11|2020-11-26|アミリス， インコーポレイテッド|PeasKaurene Oxidase for Highly Efficient Production of Revaudioside|

---

CN109704966B|2018-12-25|2021-08-20|中化健康产业发展有限公司|Method for separating components in stevia rebaudiana leaves by supercritical extraction technology|

---

CN111187316B|2020-02-14|2021-06-15|南京全凯生物基材料研究院有限公司|Method for extracting rebaudioside D and rebaudioside M from stevioside mother liquor|

法律状态:
2019-10-08| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-05-05| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|

---

2020-10-06| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2020-12-15| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2014, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US201313956144A| true| 2013-07-31|2013-07-31|

---

US13/956,144|2013-07-31|

---

PCT/EP2014/066536|WO2015014959A1|2013-07-31|2014-07-31|Recovery of steviol glycosides|

---